US Patent Issued to Elixiron Immunotherapeutics (Hong Kong) on Sept. 22 for "Anti-CD36 antibodies and uses thereof" (Taiwanese, American Inventors)

ALEXANDRIA, Va., Sept. 24 -- United States Patent no. 12,742,017, issued on Sept. 22, was assigned to Elixiron Immunotherapeutics (Hong Kong) Ltd. (Hong Kong, Hong Kong).

"Anti-CD36 antibodies and uses thereof" was invented by Hung-Kai Chen (Los Altos, Calif.), Huey-Wen Hsiao (Taipei City, Taiwan), Pandelakis Andreas Koni (Larkspur, Calif.) and Pei-Han Chung (Taipei City, Taiwan).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure provides antibodies which specifically bind to human CD36 protein (hCD36) and are capable of decreasing, inhibiting, and/or fully-blocking immune regulatory effects and/or ligand transport into cells mediated by CD36. Examples of CD36-mediated effects, among others...